AC
CTOR

Armistice Capital’s Citius Oncology CTOR Stock Holding History

Armistice Capital’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.66M Sell
8,705,589
-483,266
-5% -$385K 0.07% 129
2026
Q1 		$5.7M Buy
9,188,855
+3,604,775
+65% +$3.62M 0.1% 119
2025
Q4 		$5.58M Sell
5,584,080
-2,091,831
-27% -$3M 0.07% 124
2025
Q3 		$15.6M Buy
+7,675,911
New +$16.6M 0.23% 69

Other funds holding CTOR

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Armistice Capital's CTOR Position: Q2 2026 in Review

Armistice Capital reduced its Citius Oncology (CTOR) stake by 5.3% in Q2 2026, selling an estimated $385K and leaving 8,705,589 shares worth $5.66M. The position accounts for 0.07% of the portfolio, ranked #129.

Armistice Capital first reported a position in CTOR in Q3 2025 and has held it in 4 quarters since. The position peaked at $15.6M in Q3 2025. 19 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

  • Armistice Capital held 8,705,589 shares of Citius Oncology worth $5.66M as of Q2 2026.
  • Armistice Capital sold 483,266 Citius Oncology shares in Q2 2026, an estimated $385K.
  • Citius Oncology made up 0.07% of Armistice Capital's portfolio in Q2 2026, its #129 holding.
  • Armistice Capital first reported a position in Citius Oncology in Q3 2025 and has held it in 4 quarters since.
  • Armistice Capital's Citius Oncology position peaked at $15.6M in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.